{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/hypercalcaemia/management/known-malignancy/","result":{"pageContext":{"chapter":{"id":"4863d234-7059-57aa-b9cc-a51e3a1f3424","slug":"known-malignancy","fullItemName":"Scenario: Known malignancy","depth":2,"htmlHeader":"<!-- begin field 916a3362-b894-47df-82bd-60d4046fa848 --><h2>Scenario: Hypercalcaemia - known malignancy</h2><!-- end field 916a3362-b894-47df-82bd-60d4046fa848 -->","summary":"Covers the management of people with hypercalcaemia of known malignancy.","htmlStringContent":"<!-- begin item afa1d098-9cc4-4570-be33-97131d706a86 --><!-- begin field 7efba7cc-10fb-482c-86d0-acbc0155cd3f --><p>From age 18 years onwards.</p><!-- end field 7efba7cc-10fb-482c-86d0-acbc0155cd3f --><!-- end item afa1d098-9cc4-4570-be33-97131d706a86 -->","topic":{"id":"c0ab4dd9-cccf-54af-a952-765aa048de1d","topicId":"897bf773-43ef-4092-a798-d9eb4cbcb9cc","topicName":"Hypercalcaemia","slug":"hypercalcaemia","lastRevised":"Last revised in August 2019","chapters":[{"id":"dfffab44-62c8-5590-8bad-e41f249a89e7","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"fbfb541d-eae2-5916-af42-b77d9c9ab401","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"3c7aba33-da1a-580a-b896-fb6026eb2ad8","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"61d715de-b85d-534b-8c6f-0cf5f59814c2","slug":"changes","fullItemName":"Changes"},{"id":"48c69505-e62a-5332-a3ad-fd44bb64bd34","slug":"update","fullItemName":"Update"}]},{"id":"0105d032-866a-57c0-8c83-2f54f2b7b491","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"989b5402-77d7-5cd9-86a7-979019eba917","slug":"goals","fullItemName":"Goals"},{"id":"5d8d7c84-01cb-59e9-a02e-489cb32e799e","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"e7c39bf4-b50f-51f7-ad27-49c431acf456","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"1bb69f34-e184-554d-a518-e9d59c4f95de","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"d7060151-5501-51fc-b393-844af2c2ca54","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"7d4d8cad-82f7-5bb5-8c59-b47873b845b2","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"4408b725-f01f-596c-b319-5ef7dd246c3c","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"28f41cc2-0513-5841-9fa6-1a59bb557452","slug":"definition","fullItemName":"Definition"},{"id":"b1dd3a7e-6be5-523b-a2c5-c41f9b364798","slug":"causes","fullItemName":"Causes"},{"id":"048198e1-607a-55c4-9d7d-a63135379c28","slug":"prevalence","fullItemName":"Prevalence"},{"id":"3c5e2134-d0b1-5804-bc33-86db97dfc33b","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"62c64451-7e13-5be6-b868-01f8198a13ac","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"dc0291c2-c628-503e-a7f7-7f3fa1362b62","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"c5771a8e-2f1e-53ad-a2fc-322152fc3a3e","slug":"confirmation","fullItemName":"Confirmation"},{"id":"44ef7f17-c907-5252-8027-300e87635dc4","slug":"assessment","fullItemName":"Assessment"}]},{"id":"d005c3ba-c691-53c3-b23c-1c70928fb05d","fullItemName":"Management","slug":"management","subChapters":[{"id":"c604ea66-1be5-51cc-b014-9af770bbc709","slug":"unconfirmed-cause","fullItemName":"Scenario: Unconfirmed cause"},{"id":"4863d234-7059-57aa-b9cc-a51e3a1f3424","slug":"known-malignancy","fullItemName":"Scenario: Known malignancy"},{"id":"fb65182a-1069-5bbd-9c43-a547a8632cec","slug":"follow-up-in-primary-care","fullItemName":"Scenario: Follow-up in primary care"}]},{"id":"4017390d-3b38-5741-8d16-22624da35f3d","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"2ec3d6b5-1818-5b5f-af66-bd097d709bf2","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"847bb207-2cb8-5e5f-b3e8-ee87440a71cd","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"47a9d106-98da-5683-9641-88d123a8d071","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"a8225b5a-40b4-53e5-9095-0953daa376fa","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"c60f947f-6176-53b3-9484-54b966632a77","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"b6a6af13-45f8-5258-a611-6d8306bbe251","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"f68489fb-5d5f-5342-94a0-3979f632012b","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"d005c3ba-c691-53c3-b23c-1c70928fb05d","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"31b68d27-1639-573a-ad79-5b8b4da44d52","slug":"management","fullItemName":"Management","depth":3,"htmlHeader":"<!-- begin field ef8ddd2c-6960-427b-b255-123fa1566b91 --><h3>How should I manage a person with hypercalcaemia due to known malignancy?</h3><!-- end field ef8ddd2c-6960-427b-b255-123fa1566b91 -->","summary":null,"htmlStringContent":"<!-- begin item 3be8fb5a-e813-4f28-9717-a77c6f7544a7 --><!-- begin field 61760c83-a14e-4076-a333-72c0525e20f1 --><p><strong>If a person has a known <a class=\"topic-reference internal-reference\" href=\"/topics/hypercalcaemia/background-information/causes/\">malignancy</a> felt to be the underlying cause of hypercalcaemia:</strong></p><ul><li><strong>Discuss with the person and/or carers whether management of hypercalcaemia is appropriate,</strong> depending on clinical judgement.<ul><li>Treatment of hypercalcaemia may not be appropriate if the person is receiving palliative care and is felt to be approaching the end of life. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/palliative-care-general-issues/\">Palliative care - general issues</a> for more information.</li></ul></li><li><strong>If the person has <a class=\"topic-reference internal-reference\" href=\"/topics/hypercalcaemia/background-information/definition/\">severe</a> hypercalcaemia or severe <a class=\"topic-reference internal-reference\" href=\"/topics/hypercalcaemia/diagnosis/diagnosis/\">symptoms</a>:</strong><ul><li>Offer emergency hospital admission for further <a class=\"topic-reference internal-reference\" href=\"/topics/hypercalcaemia/management/unconfirmed-cause/#specialist-assessment-management\">specialist assessment and management</a> such as intravenous fluids and intravenous bisphosphonate therapy (pamidronate or zoledronate), depending on clinical judgement and the person's wishes.</li><li>Liaise with the person's oncologist or palliative care specialist if there is any uncertainty about ongoing management. Offer referral to a palliative care specialist for additional support and management if appropriate. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/palliative-care-general-issues/\">Palliative care - general issues</a> for more information.</li></ul></li><li><strong>If the person is asymptomatic or has minimal symptoms, with <a class=\"topic-reference internal-reference\" href=\"/topics/hypercalcaemia/background-information/definition/\">mild or moderate</a> hypercalcaemia:</strong><ul><li>Liaise with the person's oncologist or palliative care specialist if there is any uncertainty about ongoing management.</li><li>Arrange monitoring and follow-up in primary care, as appropriate. See the Scenario on <a class=\"topic-reference internal-reference\" href=\"/topics/hypercalcaemia/management/follow-up-in-primary-care/\">Follow-up in primary care</a> for more information.</li></ul></li></ul><!-- end field 61760c83-a14e-4076-a333-72c0525e20f1 --><!-- end item 3be8fb5a-e813-4f28-9717-a77c6f7544a7 -->","subChapters":[{"id":"62e5706f-7d7d-524b-bb28-0839683247ab","slug":"basis-for-recommendation-25b","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 7d51ca6e-a34c-4896-910f-54e2091ea477 --><h4>Basis for recommendation</h4><!-- end field 7d51ca6e-a34c-4896-910f-54e2091ea477 -->","summary":null,"htmlStringContent":"<!-- begin item 25bce67e-6da4-45fd-9ed1-29a6baa96128 --><!-- begin field 18cb52ba-0f44-4d6a-8754-b704f5186d93 --><p>The recommendations on management of a person with known malignancy are based on the Society for Endocrinology guideline <em>Emergency management of acute hypercalcaemia in adult patients</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Walsh, 2016</a>] and expert opinion in review articles on hypercalcaemia [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Meng, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Minisola, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Turner, 2017</a>], on parathyroid disorders [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Michels, 2013</a>], on hypercalcaemia of malignancy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Seccareccia, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Clines, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Zagzag, 2018</a>], and in a palliative care textbook <em>A guide to symptom relief in palliative care </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Regnard, 2010</a>].</p><ul><li>The recommendation to discuss whether management of hypercalcaemia is appropriate is based on the fact that malignancy-associated hypercalcaemia is a poor prognostic indicator, and correction of hypercalcaemia does not improve survival [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Seccareccia, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Zagzag, 2018</a>]. It is also based on the expert opinion of a previous external reviewer of this CKS topic, and is pragmatic, based on what CKS considers to be good clinical practice.</li><li>The recommendation to arrange emergency admission if the person has severe hypercalcaemia or severe symptoms is based on the fact this is a potential oncological emergency, which may benefit from intravenous hydration and possible intravenous bisphosphonate therapy, to urgently correct hypercalcaemia, reduce potentially distressing symptoms, and reduce the risk of life-threatening complications [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Regnard, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Clines, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Michels, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Meng, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Minisola, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Walsh, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Turner, 2017</a>].<ul><li>People with malignancy-associated hypercalcaemia are more likely to be symptomatic, as the likelihood of symptoms is related to the rate of onset of hypercalcaemia which is typically severe and of rapid-onset [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Clines, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Zagzag, 2018</a>].</li><li>Intravenous fluid therapy and correction of hypovolaemia may also improve renal function and help urinary excretion of calcium [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Zagzag, 2018</a>].</li><li>Bisphosphonate therapy has potential additional benefits of reducing bone pain and the risk of pathological fractures [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Seccareccia, 2010</a>].</li></ul></li><li>The recommendation to liaise with the person's oncologist or palliative care specialist if there is any uncertainty about ongoing management is based on expert opinion in review articles that note that treatment of the underlying malignancy may improve hypercalcaemia [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Minisola, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Zagzag, 2018</a>].</li><li>The recommendation to offer referral to a palliative care specialist is based on expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Zagzag, 2018</a>], and is also pragmatic, based on what CKS considers to be good clinical practice.</li></ul><!-- end field 18cb52ba-0f44-4d6a-8754-b704f5186d93 --><!-- end item 25bce67e-6da4-45fd-9ed1-29a6baa96128 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}